These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6450065)

  • 1. T cell subset interactions in the regulation of syngeneic tumor immunity.
    Perry LL; Greene MI
    Fed Proc; 1981 Jan; 40(1):39-44. PubMed ID: 6450065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and biological characterization of a T suppressor cell induced by anti-idiotypic antibody.
    Monroe JG; Gurish M; Dambrauskas J; Slaoui M; Lowy A; Greene MI
    J Immunol; 1985 Sep; 135(3):1589-97. PubMed ID: 3160770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of hapten-specific T and B cell responses by suppressor cells.
    Hausman PB; Sherr DH; Dorf ME
    Concepts Immunopathol; 1986; 3():38-60. PubMed ID: 2954643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential antigen presentation in tumor immunity.
    Schatten S; Drebin JA; Granstein RD; Greene MI
    Fed Proc; 1984 Jun; 43(9):2460-4. PubMed ID: 6327399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab.
    Majlessi L; Bordenave G
    Arch Immunol Ther Exp (Warsz); 2001; 49(6):407-15. PubMed ID: 11814234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory mechanisms in tumor immunity: introduction and summary.
    Rich RR
    Fed Proc; 1981 Jan; 40(1):36-8. PubMed ID: 6450064
    [No Abstract]   [Full Text] [Related]  

  • 8. Establishment of a continuous T cell line capable of suppressing anti-tumor immune responses in vivo.
    Roberts LK; Spellman CW; Warner NL
    J Immunol; 1983 Jul; 131(1):514-9. PubMed ID: 6223081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells in vivo.
    Perry LL; Benacerraf B; Greene MI
    J Immunol; 1978 Dec; 121(6):2144-7. PubMed ID: 82578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific suppressor factors of noncytotoxic CD8+ suppressor T cells downregulate antibody responses also to unrelated antigens when the latter are presented as covalently linked adducts with the specific antigen.
    Bitoh S; Takata M; Maiti PK; Holford-Strevens V; Kierek-Jaszczuk D; Sehon AH
    Cell Immunol; 1993 Aug; 150(1):168-93. PubMed ID: 8343965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback suppression: an immunoregulatory circuit.
    Eardley DD
    Fed Proc; 1980 Nov; 39(13):3114-6. PubMed ID: 6448753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen.
    Carter RH; Drebin JA; Schatten S; Perry LL; Greene MI
    J Immunol; 1983 Feb; 130(2):997-1002. PubMed ID: 6184410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of 2 types of suppressor T cells by cell surface phenotype and by function: the ability to regulate the contrasuppressor circuit.
    Green DR; Chue B; Gershon RK
    J Mol Cell Immunol; 1983; 1(1):19-30. PubMed ID: 6242848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts.
    Greene MI; Fujimoto S; Sehon AH
    J Immunol; 1977 Aug; 119(2):757-64. PubMed ID: 69667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyclonal activation of Ts cells with antiserum directed against an IGH-1 linked candidate for a T-cell receptor constant region marker.
    Owen FL
    J Supramol Struct; 1980; 14(2):175-82. PubMed ID: 6453257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-receptor relationships in immune regulation.
    Greene MI; Sy MS
    Fed Proc; 1981 Apr; 40(5):1458-61. PubMed ID: 6452289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype.
    Shearer MH; Bright RK; Kennedy RC
    Cancer Res; 1993 Dec; 53(23):5734-9. PubMed ID: 7694794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells.
    King CA; Wills MR; Hamblin TJ; Stevenson FK
    Cell Immunol; 1993 Apr; 147(2):411-24. PubMed ID: 8095858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.